Skip to main content

Table 2 Descriptive characteristics of the primary study cohort. MRI positive data is shown as the PI-RADS score of ≥ 3 or ≥ 4. Detection rates for cancer are shown for any cancer, and using definitions of ≥ Grade Group 2 (GG2 or ≥ Cambridge Prognostic Group 3 [CPG3]

From: Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study

 ≥ GG2 cancer
detection
pvalue
(vs. PSA)
≥ CPG3 cancer
detection
pvalue
(vs.PSA)
Whole cohort
PSA0.70 (0.66–0.74)0.81 (0.78–0.85)
PSAd0.79 (0.75–0.83)< 0.0010.84 (0.80–0.87)0.12
phi0.82 (0.78–0.85)< 0.0010.87 (0.84–0.90)< 0.001
MRI0.63 (0.59–0.66)< 0.001*0.63 (0.60–0.66)< 0.001*
MRI + PSA0.76 (0.72–0.80)< 0.0010.85 (0.81–0.88)0.03
MRI + PSAd0.81 (0.77–0.84)< 0.0010.85 (0.81–0.88)0.08
MRI + phi0.81 (0.78–0.85)< 0.0010.86 (0.83–0.90)0.02
MRI negative
PSA0.64 (0.52–0.76)0.86 (0.76–0.97)
PSAd0.76 (0.64–0.87)0.010.95 (0.91–0.99)0.08
phi0.78 (0.66–0.90)0.010.89 (0.74–1.00)0.76